Drug profile · INN
enfuvirtide
FUZEON
enfuvirtide (FUZEON) is a transmembrane glycoprotein gp41 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — enfuvirtide
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
enfuvirtide (FUZEON) is a transmembrane glycoprotein gp41 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Transmembrane glycoprotein gp41 inhibitor
Primary target: Transmembrane glycoprotein gp41
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is enfuvirtide?
enfuvirtide (FUZEON) is a transmembrane glycoprotein gp41 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for enfuvirtide?
FUZEON is a marketed brand name for enfuvirtide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of enfuvirtide?
enfuvirtide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.